Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 5071786, 21 pages
https://doi.org/10.1155/2017/5071786
Review Article

Modulating Neuroinflammation to Treat Neuropsychiatric Disorders

1Neuroscience and Mental Health Research Institute and School of Biosciences, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff CF24 4HQ, UK
2MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff CF24 4HQ, UK

Correspondence should be addressed to Yasir A. Syed; ku.ca.ffidrac@ydeys

Received 16 June 2017; Accepted 13 September 2017; Published 18 October 2017

Academic Editor: Daniele Tomassoni

Copyright © 2017 Franziska A. Radtke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Northoff and G. Stanghellini, “How to link brain and experience? spatiotemporal psychopathology of the lived body,” Frontiers in Human Neuroscience, vol. 10, 2016. View at Publisher · View at Google Scholar
  2. K. Bechter, H. Reiber, S. Herzog, D. Fuchs, H. Tumani, and H. G. Maxeiner, “Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction,” Journal of Psychiatric Research, vol. 44, no. 5, pp. 321–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. E. Benros, P. R. Nielsen, M. Nordentoft, W. W. Eaton, S. O. Dalton, and P. B. Mortensen, “Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study,” The American Journal of Psychiatry, vol. 168, no. 12, pp. 1303–1310, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Henje Blom, M. Lekander, M. Ingvar, M. Åsberg, F. Mobarrez, and E. Serlachius, “Pro-inflammatory cytokines are elevated in adolescent females with emotional disorders not treated with SSRIs,” Journal of Affective Disorders, vol. 136, no. 3, pp. 716–723, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Pfau and S. J. Russo, “Neuroinflammation Regulates Cognitive Impairment in Socially Defeated Mice,” Trends in Neurosciences, vol. 39, no. 6, pp. 353–355, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Bates, R. L. Kaletsky, J. R. Francica, and C. Agrawal-Gamse, “Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 106, no. 8, pp. 2886–2891, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Z. Réus, G. R. Fries, L. Stertz et al., “The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders,” Neuroscience, vol. 300, pp. 141–154, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. A. K. Al-Asmari and M. W. Khan, “Inflammation and schizophrenia: Alterations in cytokine levels and perturbation in antioxidative defense systems,” Human & Experimental Toxicology, vol. 33, no. 2, pp. 115–122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Martinez-Gras, F. Garcia-Sanchez, C. Guaza et al., “P-1270 - Cytokines levels in schizophrenia patients and in theirs first- degree biological relatives,” European Psychiatry, vol. 27, p. 1, 2012. View at Publisher · View at Google Scholar
  10. A. Sluzewska, J. Rybakowski, E. Bosmans et al., “Indicators of immune activation in major depression,” Psychiatry Research, vol. 64, no. 3, pp. 161–167, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Liu, R. C. Ho, and A. Mak, “Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression,” Journal of Affective Disorders, vol. 139, no. 3, pp. 230–239, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Vogelzangs, P. de Jonge, J. H. Smit, S. Bahn, and B. W. Penninx, “Cytokine production capacity in depression and anxiety,” Translational Psychiatry, vol. 6, no. 5, p. e825, 2016. View at Publisher · View at Google Scholar
  13. A. Remlinger-Molenda, P. Wojciak, M. Michalak, J. Karczewski, and J. K. Rybakowski, “Selected cytokine profiles during remission in bipolar patients,” Neuropsychobiology, vol. 66, no. 3, pp. 193–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Uyanik, C. Tuglu, Y. Gorgulu, H. Kunduracilar, and M. Uyanik, “Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment,” Psychiatry Research, vol. 228, no. 3, pp. 386–392, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Modabbernia, S. Taslimi, E. Brietzke, and M. Ashrafi, “Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies,” Biological Psychiatry, vol. 74, no. 1, pp. 15–25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. N. P. Rao, G. Venkatasubramanian, V. Ravi, S. Kalmady, A. Cherian, and J. R. Yc, “Plasma cytokine abnormalities in drug-naïve, comorbidity-free obsessive-compulsive disorder,” Psychiatry Research, vol. 229, no. 3, pp. 949–952, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. L. F. Fontenelle, I. G. Barbosa, J. V. Luna, L. P. de Sousa, M. N. S. Abreu, and A. L. Teixeira, “A cytokine study of adult patients with obsessive-compulsive disorder,” Comprehensive Psychiatry, vol. 53, no. 6, pp. 797–804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Guo, T. Liu, J.-C. Guo, X.-L. Jiang, F. Chen, and Y.-S. Gao, “Study on serum cytokine levels in posttraumatic stress disorder patients,” Asian Pacific Journal of Tropical Medicine, vol. 5, no. 4, pp. 323–325, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. E. A. Hoge, K. Brandstetter, S. Moshier, M. H. Pollack, K. K. Wong, and N. M. Simon, “Broad spectrum of cytokine abnormalities in Panic disorder and posttraumatic stress disorder,” Depression and Anxiety, vol. 26, no. 5, pp. 447–455, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Ashwood, P. Krakowiak, I. Hertz-Picciotto, R. Hansen, I. Pessah, and J. Van de Water, “Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome,” Brain, Behavior, and Immunity, vol. 25, no. 1, pp. 40–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Suzuki, H. Matsuzaki, K. Iwata et al., “Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders,” PLoS ONE, vol. 6, no. 5, article e20470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Gimeno, M. Kivimäki, E. J. Brunner et al., “Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study,” Psychological Medicine, vol. 39, no. 3, pp. 413–423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Fond, O. Godin, P. Llorca, and M. Leboyer, “Abnormal C-reactive protein (CRP) levels in schizophrenia and schizoaffective disorders. Results from the FACE-SZ dataset,” European Psychiatry, vol. 30, no. 8, p. S112, 2015. View at Publisher · View at Google Scholar
  24. V. Valkanova, K. P. Ebmeier, and C. L. Allan, “CRP, IL-6 and depression: A systematic review and meta-analysis of longitudinal studies,” Journal of Affective Disorders, vol. 150, no. 3, pp. 736–744, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Spitzer, S. Barnow, H. Völzke et al., “Association of posttraumatic stress disorder with low-grade elevation of C-reactive protein: evidence from the general population,” Journal of Psychiatric Research, vol. 44, no. 1, pp. 15–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Liukkonen, P. Räsänen, J. Jokelainen et al., “The association between anxiety and C-reactive protein (CRP) levels: Results from the Northern Finland 1966 Birth Cohort Study,” European Psychiatry, vol. 26, no. 6, pp. 363–369, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. M. R. Khakzad, M. Javanbakht, M. R. Shayegan et al., “The complementary role of high sensitivity C-reactive protein in the diagnosis and severity assessment of autism,” Research in Autism Spectrum Disorders, vol. 6, no. 3, pp. 1032–1037, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. P. M. Ridker, “From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection,” Circulation Research, vol. 118, no. 1, pp. 145–156, 2016. View at Publisher · View at Google Scholar
  29. G. M. Khandaker, R. M. Pearson, S. Zammit, G. Lewis, and P. B. Jones, “Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life a population-based longitudinal study,” JAMA Psychiatry, vol. 71, no. 10, pp. 1121–1128, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Saetre, L. Emilsson, E. Axelsson, J. Kreuger, E. Lindholm, and E. Jazin, “Inflammation-related genes up-regulated in schizophrenia brains,” BMC Psychiatry, vol. 7, article no. 46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Ketharanathan, A. Pereira, I. Everall, and S. Sundram, “165. Differing Expression Pattern of Epidermal Growth Factor (EGF) and Immune System Markers between Schizophrenia and Mood Disorder in the Dorsolateral Prefrontal Cortex,” Biological Psychiatry, vol. 81, no. 10, pp. S68–S69, 2017. View at Publisher · View at Google Scholar
  32. M. O. Trépanier, K. E. Hopperton, R. Mizrahi, N. Mechawar, and R. P. Bazinet, “Postmortem evidence of cerebral inflammation in schizophrenia: A systematic review,” Molecular Psychiatry, vol. 21, no. 8, pp. 1009–1026, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Mechawar and J. Savitz, “Neuropathology of mood disorders: do we see the stigmata of inflammation?” Translational Psychiatry, vol. 6, no. 11, p. e946, 2016. View at Publisher · View at Google Scholar
  34. M. E. Hernández, D. Mendieta, D. Martínez-Fong et al., “Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder,” European Neuropsychopharmacology, vol. 18, no. 12, pp. 917–924, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Capuzzi, F. Bartoli, C. Crocamo, M. Clerici, and G. Carrà, “Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: A meta-analysis,” Neuroscience & Biobehavioral Reviews, vol. 77, pp. 122–128, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Dahl, H. Ormstad, H. C. D. Aass, L. Sandvik, U. F. Malt, and O. A. Andreassen, “Recovery from major depressive disorder episode after non-pharmacological treatment is associated with normalized cytokine levels,” Acta Psychiatrica Scandinavica, vol. 134, no. 1, pp. 40–47, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Cross-Disorder and C. Cross-Disorder Group, “Group,” Nature Genetics, vol. 45, pp. 984–94, Sep 2013. View at Publisher · View at Google Scholar
  38. H. Pribiag, H. Peng, W. A. Shah, D. Stellwagen, and S. Carbonetto, “Dystroglycan mediates homeostatic synaptic plasticity at GABAergic synapses,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 111, no. 18, pp. 6810–6815, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. S. M. Purcell, N. R. Wray, J. L. Stone et al., “Common polygenic variation contributes to risk of schizophrenia and bipolar disorder,” Nature, vol. 460, no. 7256, pp. 748–752, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Sekar, A. R. Bialas, H. De Rivera et al., “Schizophrenia risk from complex variation of complement component 4,” Nature, vol. 530, no. 7589, pp. 177–183, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Ramirez-Bermudez, J. L. Soto-Hernandez, M. Lopez-Gomez, M. Mendoza-Silva, R. Colin-Piana, and C. Campillo-Serrano, “[Frequency of neuropsychiatric signs and symptoms in patients with viral encephalitis],” Rev Neurol, vol. 41, p. 140, 2005. View at Google Scholar
  42. A. Mufaddel, A. A. Omer, and M. O. Salem, “Psychiatric Aspects of Infectious Diseases,” Open Journal of Psychiatry, vol. 04, no. 03, pp. 202–217, 2014. View at Publisher · View at Google Scholar
  43. J. S. Kreutzer, R. T. Seel, and E. Gourley, “The prevalence and symptom rates of depression after traumatic brain injury: a comprehensive examination,” Brain Injury, vol. 15, no. 7, pp. 563–576, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. B. R. Lennox, E. C. Palmer-Cooper, T. Pollak et al., “Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study,” The Lancet Psychiatry, vol. 4, no. 1, pp. 42–48, 2017. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Castillo-Gomez, A. Kästner, J. Steiner et al., “The brain as immunoprecipitator of serum autoantibodies against N-Methyl-D-aspartate receptor subunit NR1,” Annals of Neurology, vol. 79, no. 1, pp. 144–151, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. C.-U. Choe, E. Karamatskos, B. Schattling et al., “A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder,” Psychiatry Research, vol. 208, no. 2, pp. 194–196, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. R. C. Dale, V. Merheb, S. Pillai et al., “Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders,” Brain, vol. 135, no. 11, pp. 3453–3468, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Tanaka, H. Matsunaga, M. Kimura et al., “Erratum: Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders (Journal of Neuroimmunology (2003) 141 (155-164)),” Journal of Neuroimmunology, vol. 144, no. 1-2, p. 148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Tanaka, H. Kuratsune, Y. Hidaka et al., “Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome.,” International Journal of Molecular Medicine, vol. 12, no. 2, pp. 225–230, 2003. View at Google Scholar · View at Scopus
  50. J. C. O'Connor, M. A. Lawson, C. André et al., “Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice,” Molecular Psychiatry, vol. 14, no. 5, pp. 511–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Dantzer, J. C. O'Connor, G. G. Freund, R. W. Johnson, and K. W. Kelley, “From inflammation to sickness and depression: when the immune system subjugates the brain,” Nature Reviews Neuroscience, vol. 9, no. 1, pp. 46–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. C. A. Ghiani, N. S. Mattan, H. Nobuta et al., “Early effects of lipopolysaccharideinduced inflammation on foetal brain development in rat,” ASN Neuro, vol. 3, no. 4, pp. 233–245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Pang, L. Campbell, B. Zheng, L. Fan, Z. Cai, and P. Rhodes, “Lipopolysaccharide-activated microglia induce death of oligodendrocyte progenitor cells and impede their development,” Neuroscience, vol. 166, no. 2, pp. 464–475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Hosoda, H. Takimura, M. Shibayama, H. Kanamura, K. Ikeda, and H. Kumada, “Psychiatric symptoms related to interferon therapy for chronic hepatitis C: Clinical features and prognosis,” Psychiatry and Clinical Neurosciences, vol. 54, no. 5, pp. 565–572, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. O. Nozaki, C. Takagi, K. Takaoka, T. Takata, and M. Yoshida, “Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: An overview of cases in Japan,” Psychiatry and Clinical Neurosciences, vol. 51, no. 4, pp. 175–180, 1997. View at Publisher · View at Google Scholar · View at Scopus
  56. O. Devinsky, A. Vezzani, S. Najjar, N. C. De Lanerolle, and M. A. Rogawski, “Glia and epilepsy: Excitability and inflammation,” Trends in Neurosciences, vol. 36, no. 3, pp. 174–184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Mandolesi, A. Gentile, A. Musella et al., “Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis,” Nature Reviews Neurology, vol. 11, no. 12, pp. 711–724, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Hagihara, K. Takao, N. M. Walton, M. Matsumoto, and T. Miyakawa, “Immature dentate gyrus: An endophenotype of neuropsychiatric disorders,” Neural Plasticity, vol. 2013, Article ID 318596, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Pont-Lezica, C. Béchade, Y. Belarif-Cantaut, O. Pascual, and A. Bessis, “Physiological roles of microglia during development,” Journal of Neurochemistry, vol. 119, no. 5, pp. 901–908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Perry, J. Court, R. Goodchild et al., “Clinical neurochemistry: Developments in dementia research based on brain bank material,” Journal of Neural Transmission, vol. 105, no. 8-9, pp. 915–933, 1998. View at Publisher · View at Google Scholar · View at Scopus
  61. F. L. Heppner, R. M. Ransohoff, and B. Becher, “Immune attack: the role of inflammation in Alzheimer disease,” Nature Reviews Neuroscience, vol. 16, no. 6, pp. 358–372, 2015. View at Publisher · View at Google Scholar
  62. S. Hong, L. Dissing-Olesen, and B. Stevens, “New insights on the role of microglia in synaptic pruning in health and disease,” Current Opinion in Neurobiology, vol. 36, pp. 128–134, 2016. View at Publisher · View at Google Scholar · View at Scopus
  63. D. M. Norden and J. P. Godbout, “Review: microglia of the aged brain: primed to be activated and resistant to regulation,” Neuropathology and Applied Neurobiology, vol. 39, no. 1, pp. 19–34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. F. Pousset, “Developmental expression of cytokine genes in the cortex and hippocampus of the rat central nervous system,” Developmental Brain Research, vol. 81, no. 1, pp. 143–146, 1994. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Pousset, “Cytokines as mediators in the central nervous system,” Biomedicine & Pharmacotherapy, vol. 48, no. 10, pp. 425–431, 1994. View at Publisher · View at Google Scholar · View at Scopus
  66. S. D. Bilbo and J. M. Schwarz, “Early-life programming of later-life brain and behavior: a critical role for the immune system,” Frontiers in Behavioral Neuroscience, vol. 3, article no. 14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. A. Yeo, J. M. Martínez Gómez, J. L. Croxford, S. Gasser, E.-A. Ling, and H. Schwarz, “CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen species,” Journal of Neuroinflammation, vol. 9, article 173, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Davalos, J. Grutzendler, G. Yang et al., “ATP mediates rapid microglial response to local brain injury in vivo,” Nature Neuroscience, vol. 8, no. 6, pp. 752–758, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Appel, P. Honegger, and P. J. Gebicke-haerter, “Expression of interleukin-3 and tumor necrosis factor-β mRNAs in cultured microglia,” Journal of Neuroimmunology, vol. 60, no. 1-2, pp. 83–91, 1995. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Buttini and H. Boddeke, “Peripheral lipopolysaccharide stimulation induces interleukin-1β messenger RNA in rat brain microglial cells,” Neuroscience, vol. 65, no. 2, pp. 523–530, 1995. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Prinz and J. Priller, “Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease,” Nature Reviews Neuroscience, vol. 15, no. 5, pp. 300–312, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. D. H. Cribbs, N. C. Berchtold, V. Perreau et al., “Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: A microarray study,” Journal of Neuroinflammation, vol. 9, article no. 179, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. P. M. Bilimoria and B. Stevens, “Microglia function during brain development: new insights from animal models,” Brain Research, 2014. View at Publisher · View at Google Scholar
  74. S.-H. Lim, E. Park, B. You et al., “Neuronal synapse formation induced by microglia and interleukin 10,” PLoS ONE, vol. 8, no. 11, Article ID e81218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. C. N. Parkhurst, G. Yang, and I. Ninan, “Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor,” Cell, vol. 155, no. 7, pp. 1596–1609, 2013. View at Publisher · View at Google Scholar
  76. L. L. Williamson, P. W. Sholar, R. S. Mistry, S. H. Smith, and S. D. Bilbo, “Microglia and memory: Modulation by early-life infection,” The Journal of Neuroscience, vol. 31, no. 43, pp. 15511–15521, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. S. D. Bilbo, J. C. Biedenkapp, A. Der-Avakian, L. R. Watkins, J. W. Rudy, and S. F. Maier, “Neonatal infection-induced memory impairment after lipopolysaccharide in adulthood is prevented via caspase-1 inhibition,” The Journal of Neuroscience, vol. 25, no. 35, pp. 8000–8009, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. R. C. Paolicelli, G. Bolasco, F. Pagani et al., “Synaptic pruning by microglia is necessary for normal brain development,” Science, vol. 333, no. 6048, pp. 1456–1458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. R. C. Paolicelli and C. T. Gross, “Microglia in development: linking brain wiring to brain environment,” Neuron Glia Biology, vol. 7, no. 1, pp. 77–83, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Schafer, E. K. Lehrman, A. G. Kautzman et al., “Microglia and the complement cascade: shaping neural circuits in the developing brain,” Schizophrenia Research, vol. 136, pp. S11–S12, 2012. View at Publisher · View at Google Scholar
  81. A. R. Bialas and B. Stevens, “TGF-β signaling regulates neuronal C1q expression and developmental synaptic refinement,” Nature Neuroscience, vol. 16, no. 12, pp. 1773–1782, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. N. Mataga, Y. Mizuguchi, and T. K. Hensch, “Experience-dependent pruning of dendritic spines in visual cortex by tissue plasminogen activator,” Neuron, vol. 44, no. 6, pp. 1031–1041, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Bhattacharjee, “Is internal timing key to mental health?” Science, vol. 317, no. 5844, pp. 1488–1490, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Bilbo, “Early Life Infection,” Microglia, and Cognition Throughout the Lifespan., Glia, vol. 61, pp. S28–S29, Jul 2013. View at Google Scholar
  85. N. Castanon, G. Luheshi, and S. Layé, “Role of neuroinflammation in the emotional and cognitive alterations displayed by animal models of obesity,” Frontiers in Neuroscience, vol. 9, article 229, 2015. View at Publisher · View at Google Scholar
  86. I. Knuesel, L. Chicha, M. Britschgi et al., “Maternal immune activation and abnormal brain development across CNS disorders,” Nature Reviews Neurology, vol. 10, no. 11, pp. 643–660, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Milior, C. Lecours, L. Samson et al., “Fractalkine receptor deficiency impairs microglial and neuronal responsiveness to chronic stress,” Brain, Behavior, and Immunity, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Steiner, C. Mawrin, A. Ziegeler et al., “Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization,” Acta Neuropathologica, vol. 112, no. 3, pp. 305–316, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Steiner, H. Bielau, R. Brisch et al., “Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide,” Journal of Psychiatric Research, vol. 42, no. 2, pp. 151–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. B. N. van Berckel, M. G. Bossong, R. Boellaard et al., “Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study,” Biological Psychiatry, vol. 64, no. 9, pp. 820–822, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Doorduin, E. F. J. de Vries, A. T. M. Willemsen, J. C. de Groot, R. A. Dierckx, and H. C. Klein, “Neuroinflammation in schizophrenia-related psychosis: a PET study,” Journal of Nuclear Medicine, vol. 50, no. 11, pp. 1801–1807, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. J. T. Morgan, G. Chana, C. A. Pardo et al., “Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism,” Biological Psychiatry, vol. 68, no. 4, pp. 368–376, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. D. Takano, T. Yamazaki, H. Masaki, M. Miyata, T. Nakase, and T. Maeda, “Regional cerebral blood flow correlates of apathy and depression in demented patients,” European Journal of Neurology, vol. 17, pp. 275–275, Sep 2010. View at Google Scholar
  94. N. A. Tetreault, A. Y. Hakeem, S. Jiang et al., “Microglia in the cerebral cortex in autism,” Journal of Autism and Developmental Disorders, vol. 42, no. 12, pp. 2569–2584, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Suzuki, T. Shiga, K. Nishimura, J. Ishigooka, and N. Hagiwara, “PHQ-9 screening for depression in hospitalized patients with heart failure,” European Journal of Heart Failure, vol. 12, pp. S242–S242, May 2013. View at Google Scholar
  96. L. Garey, “When cortical development goes wrong: Schizophrenia as a neurodevelopmental disease of microcircuits,” Journal of Anatomy, vol. 217, no. 4, pp. 324–333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. R. Foster, A. Kandanearatchi, C. Beasley et al., “Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: Evidence for an inflammatory process?” European Journal of Neuroscience, vol. 24, no. 12, pp. 3561–3566, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Notter, J. M. Coughlin, T. Gschwind et al., “Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia,” Molecular Psychiatry, 2017. View at Publisher · View at Google Scholar · View at Scopus
  99. I. Maezawa and L.-W. Jin, “Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate,” The Journal of Neuroscience, vol. 30, no. 15, pp. 5346–5356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. N. C. Derecki, J. C. Cronk, Z. Lu et al., “Wild-type microglia arrest pathology in a mouse model of Rett syndrome,” Nature, vol. 484, no. 7392, pp. 105–109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. R. Reshef, T. Kreisel, D. Beroukhim Kay, and R. Yirmiya, “Microglia and their CX3CR1 signaling are involved in hippocampal- but not olfactory bulb-related memory and neurogenesis,” Brain, Behavior, and Immunity, vol. 41, no. 1, pp. 239–250, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Tanaka, H. Fujita, S. Matsuda, K. Toku, M. Sakanaka, and N. Maeda, “Glucocorticoid- and mineralocorticoid receptors in microglial cells: The two receptors mediate differential effects of corticosteroids,” Glia, vol. 20, no. 1, pp. 23–37, 1997. View at Publisher · View at Google Scholar · View at Scopus
  103. W. J. Streit and C. A. Kincaid-Colton, “The brain's immune system,” Scientific American, vol. 273, no. 5, pp. 54–61, 1995. View at Publisher · View at Google Scholar
  104. R. M. Barrientos, M. G. Frank, A. M. Hein et al., “Time course of hippocampal IL-1 β and memory consolidation impairments in aging rats following peripheral infection,” Brain, Behavior, and Immunity, vol. 23, no. 1, pp. 46–54, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Henry, S. Bigler, and J. Wang, “High throughput analysis of neural progenitor cell proliferation in adult rodent hippocampus,” Biosci Trends, vol. 3, p. 233, Dec 2009. View at Google Scholar
  106. U. Püntener, S. G. Booth, V. H. Perry, and J. L. Teeling, “Long-term impact of systemic bacterial infection on the cerebral vasculature and microglia,” Journal of Neuroinflammation, vol. 9, article 146, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. M. W. Salter and S. Beggs, “Sublime microglia: expanding roles for the guardians of the CNS,” Cell, vol. 158, pp. 15–24, 2014. View at Publisher · View at Google Scholar
  108. M. Burmeister, L. J. Scott, J. Z. Li, D. Absher, R. C. Thompson, and F. Meng, “Identifying genes associated with bipolar disorder in the NIMII genetic study intiative samples,” vol. 11, pp. 24–24, Jul 2008.
  109. A. J. Iafrate, L. Feuk, M. N. Rivera et al., “Detection of large-scale variation in the human genome,” Nature Genetics, vol. 36, no. 9, pp. 949–951, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. R. Redon, S. Ishikawa, K. R. Fitch et al., “Global variation in copy number in the human genome,” Nature, vol. 444, no. 7118, pp. 444–454, 2006. View at Publisher · View at Google Scholar · View at Scopus
  111. E. H. Cook Jr. and S. W. Scherer, “Copy-number variations associated with neuropsychiatric conditions,” Nature, vol. 455, no. 7215, pp. 919–923, 2008. View at Publisher · View at Google Scholar · View at Scopus
  112. G. Kirov, “CNVs in neuropsychiatric disorders,” Human Molecular Genetics, vol. 24, no. 1, Article ID ddv253, pp. R45–R49, 2015. View at Publisher · View at Google Scholar · View at Scopus
  113. “Corrigendum: Mapping autism risk loci using genetic linkage and chromosomal rearrangements,” Nature Genetics, vol. 39, no. 10, pp. 1285–1285, 2007. View at Publisher · View at Google Scholar
  114. A. J. Sharp, S. Hansen, R. R. Selzer et al., “Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome,” Nature Genetics, vol. 38, no. 9, pp. 1038–1042, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. J. Stockman, “Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes,” Yearbook of Pediatrics, vol. 2010, pp. 300–302, 2010. View at Publisher · View at Google Scholar
  116. S. Ben-Shachar, B. Lanpher, J. R. German et al., “Microdeletion 15q13.3: A locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders,” Journal of Medical Genetics, vol. 46, no. 6, pp. 382–388, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. A. J. Sharp, H. C. Mefford, K. Li et al., “A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures,” Nature Genetics, vol. 40, no. 3, pp. 322–328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. D. T. Miller, Y. Shen, L. A. Weiss et al., “Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders,” Journal of Medical Genetics, vol. 46, no. 4, pp. 242–248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. C. Feinstein, S. Eliez, C. Blasey, and A. L. Reiss, “Psychiatric disorders and behavioral problems in children with velocardiofacial syndrome: Usefulness as phenotypic indicators of schizophrenia risk,” Biological Psychiatry, vol. 51, no. 4, pp. 312–318, 2002. View at Publisher · View at Google Scholar · View at Scopus
  120. A. S. Baker, T. H. Chung, T. S. Pidgeon, C. Mancini, T. Price-Troska, and S. Van Wier, “A comparative analysis of chromosome 13 gene expression and copy number changes in multiple myeloma using array-based methods,” Blood, vol. 106, pp. 447a–447a, Nov. View at Google Scholar
  121. B. Maughan, “Depression in adolescence, early adulthood and mid-life: Developmental variations in risk,” Journal of Affective Disorders, vol. 78, pp. S26–S26, Mar 2004. View at Google Scholar
  122. H.-G. Maxeiner, E. Marion Schneider, S.-T. Kurfiss, J. Brettschneider, H. Tumani, and K. Bechter, “Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases,” Cytokine, vol. 69, no. 1, pp. 62–67, 2014. View at Publisher · View at Google Scholar · View at Scopus
  123. J. C. Mulley and L. M. Dibbens, “Chipping away at the common epilepsies with complex genetics: The 15q13.3 microdeletion shows the way,” Genome Medicine, vol. 1, no. 3, article no. gm33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. I. Helbig, H. C. Mefford, A. J. Sharp et al., “15q13.3 microdeletions increase risk of idiopathic generalized epilepsy,” Nature Genetics, vol. 41, no. 2, pp. 160–162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. H. Muhle, H. C. Mefford, T. Obermeier et al., “Absence seizures with intellectual disability as a phenotype of the 15q13.3 microdeletion syndrome,” Epilepsia, vol. 52, no. 12, pp. e194–e198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. H. Stefansson, D. Rujescu, S. Cichon, O. P. H. Pietilainen, A. Ingason, and S. Steinberg, “Large recurrent microdeletions associated with schizophrenia,” Nature, vol. 455, pp. 232–61, Sep. View at Google Scholar
  127. E. Vassos, D. A. Collier, S. Holden et al., “Penetrance for copy number variants associated with schizophrenia,” Human Molecular Genetics, vol. 19, no. 17, Article ID ddq259, pp. 3477–3481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. D. F. Levinson, J. Duan, S. Oh et al., “Copy number variants in schizophrenia: Confirmation of five previous finding sand new evidence for 3q29 microdeletions and VIPR2 duplications,” The American Journal of Psychiatry, vol. 168, no. 3, pp. 302–316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  129. V. Vacic, S. McCarthy, D. Malhotra et al., “Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia (Nature (2011) 471 (499-501)),” Nature, vol. 474, no. 7349, p. 114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. M. Shinawi, C. P. Schaaf, S. S. Bhatt et al., “A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypes,” Nature Genetics, vol. 41, no. 12, pp. 1269–1271, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. A. T. Pagnamenta, K. Wing, E. S. Akha et al., “A 15q13.3 microdeletion segregating with autism,” European Journal of Human Genetics, vol. 17, no. 5, pp. 687–692, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. J. P. Szatkiewicz, C. O'Dushlaine, and G. Chen, “Copy number variation in schizophrenia in Sweden,” Molecular Psychiatry, vol. 19, pp. 762–773, 2014. View at Publisher · View at Google Scholar
  133. Y. Lee, A. Mattai, R. Long, J. L. Rapoport, N. Gogtay, and A. M. Addington, “Microduplications disrupting the MYT1L gene (2p25.3) are associated with schizophrenia,” Psychiatric Genetics, vol. 22, no. 4, pp. 206–209, 2012. View at Publisher · View at Google Scholar
  134. L. A. Weiss, Y. Shen, and J. M. Korn, “Association between microdeletion and microduplication at 16p11.2 and autism,” The New England Journal of Medicine, vol. 358, no. 7, pp. 667–675, 2008. View at Publisher · View at Google Scholar · View at Scopus
  135. X. Zheng, F. Y. Demirci, M. M. Barmada et al., “A rare duplication on chromosome 16p11.2 is identified in patients with psychosis in Alzheimer's disease,” PLoS ONE, vol. 9, no. 11, Article ID e111462, 2014. View at Publisher · View at Google Scholar · View at Scopus
  136. A. J. Pocklington, E. Rees, J. T. R. Walters et al., “Novel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia,” Neuron, vol. 86, no. 5, pp. 1203–1214, 2015. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Fromer, A. J. Pocklington, D. H. Kavanagh et al., “De novo mutations in schizophrenia implicate synaptic networks,” Nature, vol. 506, no. 7487, pp. 179–184, 2014. View at Publisher · View at Google Scholar · View at Scopus
  138. J. L. Haines, B. R. Korf, C. C. Morton, C. E. Seidman, J. Seidman, and D. R. Smith, Current Protocols in Human Genetics, John Wiley & Sons, Inc., Hoboken, NJ, USA, 2001.
  139. G. Kirov, A. J. Pocklington, P. Holmans et al., “De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia,” Molecular Psychiatry, vol. 17, no. 2, pp. 142–153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  140. L. M. Piliero, A. N. Sanford, D. M. McDonald-McGinn, E. H. Zackai, and K. E. Sullivan, “T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome,” Blood, vol. 103, no. 3, pp. 1020–1025, 2004. View at Publisher · View at Google Scholar · View at Scopus
  141. D. M. Aresvik, K. Lima, T. Øverland, T. E. Mollnes, and T. G. Abrahamsen, “Increased Levels of Interferon-Inducible Protein 10 (IP-10) in 22q11.2 Deletion Syndrome,” Scandinavian Journal of Immunology, vol. 83, no. 3, pp. 188–194, 2016. View at Publisher · View at Google Scholar · View at Scopus
  142. H. E. Ross, Y. Guo, K. Coleman, O. Ousley, and A. H. Miller, “Association of IL-12p70 and IL-6: IL-10 ratio with autism-related behaviors in 22q11.2 deletion syndrome: A preliminary report,” Brain, Behavior, and Immunity, vol. 31, pp. 76–81, 2013. View at Publisher · View at Google Scholar · View at Scopus
  143. R. Zemble, E. Luning Prak, K. McDonald, D. McDonald-McGinn, E. Zackai, and K. Sullivan, “Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome),” Clinical Immunology, vol. 136, no. 3, pp. 409–418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. M. Toyoshima, W. Akamatsu, Y. Okada et al., “Analysis of induced pluripotent stem cells carrying 22q11.2 deletion,” Translational Psychiatry, vol. 6, no. 11, article no. e934, 2016. View at Publisher · View at Google Scholar · View at Scopus
  145. L. Philippe, G. Alsaleh, S. Bahram, S. Pfeffer, and P. Georgel, “The miR-17 ~ 92 cluster: A key player in the control of inflammation during rheumatoid arthritis,” Frontiers in Immunology, vol. 4, Article ID Article 70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  146. H. H. Qin, X. H. Zhu, J. Liang, J. F. Wu, Y. S. Yang, and J. H. Xu, “The expression and significance of miR-17-92 cluster miRs in CD4(+) T cells from patients with systemic lupus erythernatosus,” Clinical and Experimental Rheumatology, vol. 31, pp. 472-473, 2013. View at Google Scholar
  147. Z. Zhai, F. Wu, A. Y. Chuang, and J. H. Kwon, “MiR-106b fine tunes ATG16L1 expression and autophagic activity in intestinal epithelial HCT116 cells,” Inflammatory Bowel Diseases, vol. 19, no. 11, pp. 2295–2301, 2013. View at Publisher · View at Google Scholar · View at Scopus
  148. R. J. Shprintzen, A. M. Higgins, K. Antshel, W. Fremont, N. Roizen, and W. Kates, “Velo-cardio-facial syndrome,” Current Opinion in Pediatrics, vol. 17, no. 6, pp. 725–730, 2005. View at Publisher · View at Google Scholar · View at Scopus
  149. J.-B. Le Pichon, S. Yu, N. Kibiryeva, W. D. Graf, and D. C. Bittel, “Genome-wide gene expression in a patient with 15q13.3 homozygous microdeletion syndrome,” European Journal of Human Genetics, vol. 21, no. 10, pp. 1093–1099, 2013. View at Publisher · View at Google Scholar · View at Scopus
  150. M. S. Hong, J. Y. Song, D. H. Yun, J.-J. Cho, and J.-H. Chung, “Increase of NADPH-diaphorase expression in hypothalamus of Stat4 knockout mice,” Korean Journal of Physiology & Pharmacology, vol. 13, no. 5, pp. 337–341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. V. Calabrese, C. Mancuso, M. Calvani, E. Rizzarelli, D. A. Butterfield, and A. M. G. Stella, “Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity,” Nature Reviews Neuroscience, vol. 8, no. 10, pp. 766–775, 2007. View at Publisher · View at Google Scholar · View at Scopus
  152. M. L. Capone, S. Tacconelli, M. G. Sciulli, and P. Patrignani, “Clinical pharmacology of selective COX-2 inhibitors,” International Journal of Immunopathology and Pharmacology, vol. 16, no. 2, pp. 49–58, 2003. View at Publisher · View at Google Scholar · View at Scopus
  153. A. Kaizaki, L.-T. Tien, Y. Pang et al., “Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide,” Journal of Neuroinflammation, vol. 10, article no. 45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  154. N. Müller and M. J. Schwarz, “The immunological basis of glutamatergic disturbance in schizophrenia: Towards an integrated view,” Journal of Neural Transmission. Supplementa, no. 72, pp. 269–280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. S. Erhardt, L. Schwieler, and G. Engberg, “Kynurenic Acid And Schizophrenia,” in Developments in Tryptophan and Serotonin Metabolism, vol. 527 of Advances in Experimental Medicine and Biology, pp. 155–165, Springer US, Boston, MA, 2003. View at Publisher · View at Google Scholar
  156. C. Chaves, C. R. Marque, L. Wichert-Ana, J. P. Maia-de-Oliveira, E. N. Itikawa, and J. A. D. Crippa, “Minocycline and psychoneuroimmunology in schizophrenia, Progress in Neuro-Psychopharmacology Biological Psychiatry,” Minocycline and psychoneuroimmunology in schizophrenia, Progress in Neuro-Psychopharmacology Biological Psychiatry, vol. 34, pp. 1133-1134, Aug. View at Google Scholar
  157. H. Kim and Y. Suh, “Minocycline and neurodegenerative diseases,” Behavioural Brain Research, vol. 196, no. 2, pp. 168–179, 2009. View at Publisher · View at Google Scholar · View at Scopus
  158. W. Laan, D. E. Grobbee, J.-P. Selten, C. J. Heijnen, R. S. Kahn, and H. Burger, “Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial,” Journal of Clinical Psychiatry, vol. 71, no. 5, pp. 520–527, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. M. Weiser, S. Burstein, L. Fodoreanu et al., “Positive symptoms respond to add-on aspirin in schizophrenia patients with high sera CRP levels: a post-hoc analysis of an RCT,” Schizophrenia Research, vol. 153, p. S79, 2014. View at Publisher · View at Google Scholar
  160. N. Müller, M. Riedel, C. Scheppach et al., “Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia,” The American Journal of Psychiatry, vol. 159, no. 6, pp. 1029–1034, 2002. View at Publisher · View at Google Scholar · View at Scopus
  161. T. Baheti, A. Nischal, A. Nischal et al., “A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia,” Schizophrenia Research, vol. 147, no. 1, pp. 201-202, 2013. View at Publisher · View at Google Scholar · View at Scopus
  162. S. Akhondzadeh, M. Tabatabaee, H. Amini, S. A. Ahmadi Abhari, S. H. Abbasi, and B. Behnam, “Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial,” Schizophrenia Research, vol. 90, no. 1–3, pp. 179–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  163. N. Müller, D. Krause, S. Dehning et al., “Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment,” Schizophrenia Research, vol. 121, no. 1–3, pp. 118–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  164. M. H. Rapaport, K. K. Delrahim, C. J. Bresee, R. E. Maddux, O. Ahmadpour, and D. Dolnak, “Celecoxib augmentation of continuously Ill patients with schizophrenia,” Biological Psychiatry, vol. 57, no. 12, pp. 1594–1596, 2005. View at Publisher · View at Google Scholar · View at Scopus
  165. O. Köhler, L. Petersen, M. E. Benros, O. Mors, and C. Gasse, “Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse – a population-based study of 16,253 incident patients with schizophrenia,” Expert Opinion on Pharmacotherapy, vol. 17, no. 8, pp. 1055–1062, 2016. View at Publisher · View at Google Scholar · View at Scopus
  166. W. Laan, J.-P. Selten, D. E. Grobbee, H. Smeets, R. S. Kahn, and H. Burger, “Non-steroidal anti-inflammatory drugs and the risk of psychosis,” European Neuropsychopharmacology, vol. 17, no. 4, pp. 309–311, 2007. View at Publisher · View at Google Scholar · View at Scopus
  167. P. Stolk, P. C. Souverein, H. G. M. Leufkens, J. G. Weil, A. C. G. Egberts, and E. R. Heerdink, “The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study,” Pharmacopsychiatry, vol. 40, no. 3, pp. 111–115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  168. I. B. Chaudhry, J. Hallak, N. Husain et al., “Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment,” Journal of Psychopharmacology, vol. 26, no. 9, pp. 1185–1193, 2012. View at Publisher · View at Google Scholar · View at Scopus
  169. F. Liu, X. Guo, R. Wu et al., “Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial,” Schizophrenia Research, vol. 153, no. 1-3, pp. 169–176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  170. A. Ghanizadeh, S. Dehbozorgi, M. OmraniSigaroodi, and Z. Rezaei, “Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial,” Recent Patents on Inflammation & Allergy Drug Discovery, vol. 8, no. 3, pp. 211–215, 2014. View at Publisher · View at Google Scholar · View at Scopus
  171. M.-R. Khodaie-Ardakani, O. Mirshafiee, M. Farokhnia et al., “Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study,” Psychiatry Research, vol. 215, no. 3, pp. 540–546, 2014. View at Publisher · View at Google Scholar · View at Scopus
  172. Y. Levkovitz, S. Mendlovich, S. Riwkes et al., “A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia,” Journal of Clinical Psychiatry, vol. 71, no. 2, pp. 138–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  173. O. Köhler-Forsberg, L. Sylvia, M. Thase et al., “Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder,” Depression and Anxiety, vol. 34, no. 3, pp. 281–290, 2017. View at Publisher · View at Google Scholar · View at Scopus
  174. S. Saroukhani, M. Emami-Parsa, A. Modabbernia et al., “Aspirin for treatment of lithium-associated sexual dysfunction in men: Randomized double-blind placebo-controlled study,” Bipolar Disorder, vol. 15, no. 6, pp. 650–656, 2013. View at Publisher · View at Google Scholar · View at Scopus
  175. P. Stolk, P. C. Souverein, I. Wilting et al., “Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 82, no. 1, pp. 9–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  176. F. G. Nery, E. S. Monkul, J. P. Hatch et al., “Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study,” Journal of Psychopharmacology, vol. 23, no. 2, pp. 87–94, 2008. View at Publisher · View at Google Scholar · View at Scopus
  177. S. Arabzadeh, N. Ameli, A. Zeinoddini et al., “Celecoxib adjunctive therapy for acute bipolar mania: A randomized, double-blind, placebo-controlled trial,” Bipolar Disorder, vol. 17, no. 6, pp. 606–614, 2015. View at Publisher · View at Google Scholar · View at Scopus
  178. R. Uher, S. Carver, R. A. Power et al., “Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder,” Psychological Medicine, vol. 42, no. 10, pp. 2027–2035, 2012. View at Publisher · View at Google Scholar · View at Scopus
  179. O. P. Almeida, H. Alfonso, K. Jamrozik, G. J. Hankey, and L. Flicker, “Aspirin use, depression, and cognitive impairment in later life: The health in men study,” Journal of the American Geriatrics Society, vol. 58, no. 5, pp. 990–992, 2010. View at Publisher · View at Google Scholar · View at Scopus
  180. J. Glaus, C. L. Vandeleur, A. M. Lasserre et al., “Aspirin and statin use and the subsequent development of depression in men and women: Results from a longitudinal population-based study,” Journal of Affective Disorders, vol. 182, pp. 126–131, 2015. View at Publisher · View at Google Scholar · View at Scopus
  181. K. S. Na, K. J. Lee, J. S. Lee, Y. S. Cho, and H. Y. Jung, “Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: A meta-analysis,” in Progress in Neuro-Psychopharmacology Biological Psychiatry, vol. 48, pp. 79–85, Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder, A meta-analysis, 2014. View at Publisher · View at Google Scholar
  182. P. Mohammadinejad, P. Arya, M. Esfandbod et al., “Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial,” Annals of Pharmacotherapy, vol. 49, no. 9, pp. 953–961, 2015. View at Publisher · View at Google Scholar · View at Scopus
  183. S. Jafari, S.-G. Ashrafizadeh, A. Zeinoddini et al., “Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial,” Journal of Clinical Pharmacy and Therapeutics, vol. 40, no. 4, pp. 441–446, 2015. View at Publisher · View at Google Scholar · View at Scopus
  184. C. Fields, L. Drye, V. Vaidya, and C. Lyketsos, “Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: Findings from a randomized controlled trial,” The American Journal of Geriatric Psychiatry, vol. 20, no. 6, pp. 505–513, 2012. View at Publisher · View at Google Scholar · View at Scopus
  185. T. Miyaoka, R. Wake, M. Furuya et al., “Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 37, no. 2, pp. 222–226, 2012. View at Publisher · View at Google Scholar · View at Scopus
  186. H. Emadi-Kouchak, P. Mohammadinejad, A. Asadollahi-Amin et al., “Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: A double-blind, placebo-controlled, randomized trial,” International Clinical Psychopharmacology, vol. 31, no. 1, pp. 20–26, 2016. View at Publisher · View at Google Scholar · View at Scopus
  187. M. Shalbafan, P. Mohammadinejad, S.-V. Shariat et al., “Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial,” Pharmacopsychiatry, vol. 48, no. 4-5, pp. 136–140, 2015. View at Publisher · View at Google Scholar · View at Scopus
  188. H. Afshar, H. Roohafza, H. Mohammad-Beigi et al., “N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial,” Journal of Clinical Psychopharmacology, vol. 32, no. 6, pp. 797–803, 2012. View at Publisher · View at Google Scholar · View at Scopus
  189. C. I. Rodriguez, J. Bender Jr., S. M. Marcus, M. Snape, M. Rynn, and H. B. Simpson, “Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: An open-label trial,” Journal of Clinical Psychiatry, vol. 71, no. 9, pp. 1247–1249, 2010. View at Publisher · View at Google Scholar · View at Scopus
  190. S. Esalatmanesh, Z. Abrishami, A. Zeinoddini et al., “Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive–compulsive disorder: A placebo-controlled, double-blind, randomized trial,” Psychiatry and Clinical Neurosciences, vol. 70, no. 11, pp. 517–526, 2016. View at Publisher · View at Google Scholar · View at Scopus
  191. M. Asadabadi, M.-R. Mohammadi, A. Ghanizadeh et al., “Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial,” Psychopharmacology, vol. 225, no. 1, pp. 51–59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  192. C. A. Pardo, A. Buckley, A. Thurm et al., “A pilot open-label trial of minocycline in patients with autism and regressive features,” Journal of Neurodevelopmental Disorders, vol. 5, no. 1, pp. 1–9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  193. D. L. Kelly, K. M. Sullivan, J. P. McEvoy et al., “Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients with Persistent Symptoms,” Journal of Clinical Psychopharmacology, vol. 35, no. 4, pp. 374–381, 2015. View at Publisher · View at Google Scholar · View at Scopus
  194. M. I. Husain, I. B. Chaudhry, M. M. Hamirani et al., “Minocycline and celecoxib as adjunctive treatments for bipolar depression: A study protocol for a multicenter factorial design randomized controlled trial,” Neuropsychiatric Disease and Treatment, vol. 13, 2017. View at Publisher · View at Google Scholar · View at Scopus
  195. J. Savitz, S. Preskorn, T. K. Teague, D. Drevets, W. Yates, and W. Drevets, “Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, doubleblind, placebo-controlled, 232 clinical trial,” BMJ Open, vol. 2, no. 1, Article ID 000643, 2012. View at Publisher · View at Google Scholar · View at Scopus
  196. P. J. Gallagher, V. Castro, M. Fava et al., “Antidepressant response in patients with major depression exposed to NSAIDs: A pharmacovigilance study,” The American Journal of Psychiatry, vol. 169, no. 10, pp. 1065–1072, 2012. View at Publisher · View at Google Scholar · View at Scopus
  197. P. M. Grace, L. C. Loram, J. P. Christianson et al., “Behavioral assessment of neuropathic pain, fatigue, and anxiety in experimental autoimmune encephalomyelitis (EAE) and attenuation by interleukin-10 gene therapy,” Brain, Behavior, and Immunity, vol. 59, pp. 49–54, 2017. View at Publisher · View at Google Scholar · View at Scopus
  198. E. Siopi, G. Llufriu-Dabén, F. Fanucchi, M. Plotkine, C. Marchand-Leroux, and M. Jafarian-Tehrani, “Evaluation of late cognitive impairment and anxiety states following traumatic brain injury in mice: the effect of minocycline,” Neuroscience Letters, vol. 511, no. 2, pp. 110–115, 2012. View at Publisher · View at Google Scholar · View at Scopus
  199. J. Majidi, M. Kosari-Nasab, and A.-A. Salari, “Developmental minocycline treatment reverses the effects of neonatal immune activation on anxiety- and depression-like behaviors, hippocampal inflammation, and HPA axis activity in adult mice,” Brain Research Bulletin, vol. 120, pp. 1–13, 2016. View at Publisher · View at Google Scholar · View at Scopus
  200. R. Hou, M. Garner, C. Holmes et al., “Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study,” Brain, Behavior, and Immunity, vol. 62, pp. 212–218, 2017. View at Publisher · View at Google Scholar · View at Scopus
  201. N. Vogelzangs, A. T. F. Beekman, P. De Jonge, and B. W. J. H. Penninx, “Anxiety disorders and inflammation in a large adult cohort,” Translational Psychiatry, vol. 3, article e249, 2013. View at Publisher · View at Google Scholar · View at Scopus
  202. F. Uguz, C. Akman, S. Kucuksarac, and O. Tufekci, “Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis,” Psychiatry and Clinical Neurosciences, vol. 63, no. 1, pp. 50–55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  203. K. Sulakhiya, G. P. Keshavlal, B. B. Bezbaruah et al., “Lipopolysaccharide induced anxiety- and depressive-like behaviour in mice are prevented by chronic pre-treatment of esculetin,” Neuroscience Letters, vol. 611, pp. 106–111, 2016. View at Publisher · View at Google Scholar · View at Scopus
  204. S. Valcheva-Kuzmanova and M. Zhelyazkova-Savova, “Anxiolytic-like effect of Aronia melanocarpa fruit juice in rats,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 31, no. 10, pp. 651–654, 2009. View at Publisher · View at Google Scholar · View at Scopus
  205. A. S. Reis, M. Pinz, L. F. B. Duarte et al., “4-phenylselenyl-7-chloroquinoline, a novel multitarget compound with anxiolytic activity: Contribution of the glutamatergic system,” Journal of Psychiatric Research, vol. 84, pp. 191–199, 2017. View at Publisher · View at Google Scholar · View at Scopus
  206. K. Sulakhiya, P. Kumar, S. S. Gurjar, C. C. Barua, and N. K. Hazarika, “Beneficial effect of honokiol on lipopolysaccharide induced anxiety-like behavior and liver damage in mice,” Pharmacology Biochemistry & Behavior, vol. 132, pp. 79–87, 2015. View at Publisher · View at Google Scholar · View at Scopus
  207. S. Moylan, H. A. Eyre, M. Maes, B. T. Baune, F. N. Jacka, and M. Berk, “Exercising the worry away: how inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours,” Neuroscience & Biobehavioral Reviews, vol. 37, no. 4, pp. 573–584, 2013. View at Publisher · View at Google Scholar · View at Scopus